MYRX Share Price

Open 0.06 Change Price %
High 0.10 1 Day 0.05 100.00
Low 0.06 1 Week 0.04 66.67
Close 0.10 1 Month 0.06 150.00
Volume 238515 1 Year 0.02 25.00
52 Week High 0.10
52 Week Low 0.00
MYRX Important Levels
Resistance 2 0.14
Resistance 1 0.12
Pivot 0.09
Support 1 0.08
Support 2 0.06
NASDAQ USA Most Active Stocks
DRYS 2.24 -4.68%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
ASTI 0.00 0.00%
More..
NASDAQ USA Top Gainers Stocks
MYRX 0.10 100.00%
LOCM 0.09 50.00%
CEMP 4.05 28.57%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
SKBI 0.10 25.00%
IPCI 2.55 18.60%
QKLS 0.15 15.38%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
GMETP 0.70 -59.54%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
EDMC 0.01 -50.00%
QTWW 0.08 -50.00%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
More..

Myrexis, Inc (NASDAQ: MYRX)

MYRX Technical Analysis 4
As on 24th Feb 2017 MYRX Share Price closed @ 0.10 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.06 & Strong Buy for SHORT-TERM with Stoploss of 0.04 we also expect STOCK to react on Following IMPORTANT LEVELS.
MYRX Target for February
1st Target up-side 0.07
2nd Target up-side 0.09
3rd Target up-side 0.11
1st Target down-side 0.01
2nd Target down-side -0.01
3rd Target down-side -0.03
MYRX Other Details
Segment EQ
Market Capital 64093332.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.myrexis.com
MYRX Address
MYRX
630 Fifth Avenue
Suite 2260
New York, NY 10020
United States
Phone: 801-214-7800
MYRX Latest News
Stock Update (NASDAQ:PTX): Pernix Therapeutics Holdings Inc Appoints Two Board ...   Smarter Analyst   - 08th Nov 16
Affymax, Inc. Announces a Special Cash Distribution and the Appointment of a ...   Business Wire (press release)   - 27th Nov 14
Recursion Pharmaceuticals Announces Robert Lollini as the Second Member of ...   Business Wire (press release)   - 03rd Nov 14
Myrexis: Cheap Opportunity On Proven Management Team   Seeking Alpha   - 03rd Mar 14
Myrexis, Inc. Announces the Cancellation of Its Upcoming Shareholder Meeting   GlobeNewswire (press release)   - 23rd Jan 13
BioFire Diagnostics, Inc. Names Robert Lollini Chief Financial Officer   GlobeNewswire (press release)   - 01st Nov 12
Longtime biotech exec Richard Brewer dies from multiple myeloma   Bizjournals.com (blog)   - 15th Aug 12
EpiCept Transfers Ceplene Responsibilities in European Union and Sells License ...   Business Wire (press release)   - 19th Jun 12
EpiCept's Licensed Compound EP1013 Identified as a New Drug Candidate for ...   Business Wire (press release)   - 04th Apr 12
Myriad Pharmaceuticals Formally Adopts Its Name Change to Myrexis, Inc ...   GlobeNewsWire (press release)   - 01st Jul 10
Interactive Technical Analysis Chart Myrexis, Inc ( MYRX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Myrexis, Inc
MYRX Business Profile
Myrexis Inc, is a biopharmaceutical company that has generated a pipeline of differentiated drug candidates in oncology and autoimmune diseases. The Company retains all rights to all of its drug candidates and programs across all geographic markets and therapeutic indications. In February 2012, the Company suspended development activities in oncology programs and are actively pursuing business development opportunities with respect to them. In February 2012, the Company suspended development activity on all of its preclinical and clinical programs and retained Stifel Nicolaus Weisel, an investment banking firm, to assist in reviewing and evaluating a range of strategic alternatives to enhance shareholder value.